Breast Cancer

FDA approves early stage breast cancer drug

Published in Cancer Weekly, September 7th, 2004

Pharmaceutical company Aventis has announced that it has won U.S. Food and Drug Administration approval of its drug Taxotere for treatment of women with early stage breast cancer.

The FDA approval expands Taxotere's use, which was previously used for women with advanced breast cancer after chemotherapy failed.

Aventis says it sees great promise for use of Taxotere in treating a variety of cancers. The company won FDA approval in May for using the drug as a prostate cancer treatment for men resistant to hormone therapy.

Aventis also plans to seek approval for Taxotere as a treatment for gastric cancer and head and neck...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2004-09-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry